Mira Tohmé, PhD

nkarta therapeutics
South San Francisco, CA, United States

Translational Research in cellular therapies

Presentation(s):

• 0014: NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, induces deep CD19+ B cell depletion in hematological malignancy and models of autoimmune disease

  Sunday, October 26, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): No financial relationships with ineligible companies to disclose